Novo Nordisk narrows 2024 guidance range
Novo Nordisk has today reported better-than-expected quarterly sales of its popular Wegovy weight-loss drug and narrowed its 2024 outlook for the year, in a mixed set of results reflecting growing competition in the fast-growing obesity drug market.
Business
• 06 Nov 24
